Share Price | Oculis Holding AG Stock Analysis & Recommendation

Q: What does Oculis Holding AG do?

Overview: Oculis Holding AG operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.Financial Snapshot: Net Profit: -37 Million (Quarterly Results - Mar 2025) Market Cap: USD 1,193.22 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.12 Return on Equity: -43.40% Price to Book: 6.49Contact Details: Registrar Address: Not available.

Q: Is Oculis Holding AG technically bullish or bearish?

As of 31 October 2025, the technical trend for Oculis Holding AG has changed from mildly bullish to sideways. The current stance is neutral, with mixed signals across different time frames. The weekly MACD is bullish, while the monthly MACD is mildly bearish. Bollinger Bands indicate bullishness on both weekly and monthly charts. However, moving averages are mildly bearish on the daily timeframe, and Dow Theory shows a mildly bearish trend on the weekly basis. In terms of performance, Oculis has underperformed the S&P 500 over the past week and year, with a return of -10.6% compared to the S&P's 0.71% for the week, and 7.77% versus 19.89% for the year. However, it has outperformed the S&P 500 over the 3-year period with a return of 92.89% compared to 76.66%.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

282.0 k

Shareholding (Dec 2025)

FII

16.64%

Held by 18 FIIs

DII

62.89%

Held by 6 DIIs

Promoter

16.35%

How big is Oculis Holding AG?

22-Jun-2025

As of Jun 18, Oculis Holding AG has a market capitalization of 1,193.22 million and reported net sales of 0.00 million with a net profit of -115.95 million for the latest four quarters. Shareholder's funds are 80.97 million and total assets amount to 132.80 million.

View full answer

What does Oculis Holding AG do?

22-Jun-2025

Oculis Holding AG is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $37 million and a market cap of $1.19 billion. Key financial metrics include a negative P/E ratio, a 0% dividend yield, and a return on equity of -43.40%.

View full answer

Is Oculis Holding AG technically bullish or bearish?

05-Nov-2025

As of October 31, 2025, Oculis Holding AG's trend is neutral with mixed signals, showing a mildly bullish weekly MACD but a mildly bearish monthly MACD, and while it has underperformed the S&P 500 recently, it has outperformed over the past three years.

View full answer

Compare Oculis Holding AG with Similar Stocks

Zymeworks, Inc.Biomea Fusion, Inc.Theravance Biopharma, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 1,579 Million (Small Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.11

Return on Equity

-58.75%

Price to Book

9.62

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2025)

Net Profit:

-29 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

27.62%

6 Months

42.87%

1 Year

31.05%

2 Years

109.79%

3 Years

210.17%

4 Years

155.76%

5 Years

0.0%

Oculis Holding AG for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

0.00%

EBIT Growth (5y)

-163.83%

EBIT to Interest (avg)

-44.53

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.12

Sales to Capital Employed (avg)

Tax Ratio

0.19%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

31.81%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

9.62

EV to EBIT

-14.97

EV to EBITDA

-15.07

EV to Capital Employed

-78.45

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-58.75%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Bullish

Mildly Bearish

Dow Theory

Mildly Bearish

Mildly Bullish

OBV

No Trend

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 7 Schemes (4.13%)

Foreign Institutions

Held by 18 Foreign Institutions (16.64%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 10.09% vs -131.91% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-26.30",
          "val2": "-19.50",
          "chgp": "-34.87%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.30",
          "val2": "0.30",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-4.10",
          "val2": "-15.30",
          "chgp": "73.20%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-29.40",
          "val2": "-32.70",
          "chgp": "10.09%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -22.38% vs 1.42% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-99.10",
          "val2": "-83.40",
          "chgp": "-18.82%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.00",
          "val2": "0.70",
          "chgp": "42.86%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-14.80",
          "val2": "-17.60",
          "chgp": "15.91%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-119.20",
          "val2": "-97.40",
          "chgp": "-22.38%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-26.30

-19.50

-34.87%

Interest

0.30

Exceptional Items

-4.10

-15.30

73.20%

Consolidate Net Profit

-29.40

-32.70

10.09%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is 10.09% vs -131.91% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-99.10

-83.40

-18.82%

Interest

1.00

0.70

42.86%

Exceptional Items

-14.80

-17.60

15.91%

Consolidate Net Profit

-119.20

-97.40

-22.38%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -22.38% vs 1.42% in Dec 2024

All Annual Results

Company CV

About Oculis Holding AG

Oculis Holding AG

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available